Abstract
The detection of disease recurrence and treatment monitoring pose high demands on diagnostic modalities. Whereas serum marker levels in most cases allow an assessment of tumor load and a respective response to therapy, they do not confer information on the localization of disease. Although this diagnostic gap is filled by imaging modalities, most techniques based on morphology will come to a limit when fibrotic tissue alterations have to be differentiated from viable tumor tissue in case of suspected recurrence or when residual masses after chemotherapy have to be assessed. The metabolic information on tumor cells gained by fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging appears not only to be more sensitive and reliable in this respect, but also appears to allow assumptions on response to therapy, and ultimately on patient prognosis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Amthauer H, Denecke T, Rau B, Hildebrandt B, Hunerbein M, Ruf J, Schneider U, Gutberlet M, Schlag PM, Felix R, Wust P (2004) Response prediction by FDG-PET after neoadjuvant radiochemotherapy and regional hyperthermia of rectal cancer: correlation with endorectal ultrasound and histopathology. Eur J Nucl Med Mol Imaging 31:811–819
Birk D, Fortnagel G, Formentini A, Beger HG (1998) Small carcinoma of the pancreas. Factors of prognostic relevance. J Hepatobiliary Pancreat Surg 5:450–454
Cleary SP, Gryfe R, Guindi M, Greig P, Smith L, Mackenzie R, Strasberg S, Hanna S, Taylor B, Langer B, Gallinger S (2004) Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 198:722–731
Diederichs CG, Staib L, Glatting G, Beger HG, Reske SN (1998) FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 39:1030–1033
Egawa S, Takeda K, Fukuyama S, Motoi F, Sunamura M, Matsuno S (2004) Clinicopathological aspects of small pancreatic cancer. Pancreas 28:235–240
Franke C, Klapdor R, Meyerhoff K, Schauman M (1999) 18-FDG positron emission tomography of the pancreas: diagnostic benefit in the follow-up of pancreatic carcinoma. Anticancer Res 19:2437–2442
Goggins MG (2005) The molecular diagnosis of pancreatic cancer. In: Von Hoff DD, Evans DB, Hruban RH (eds) Pancreatic cancer. Jones and Bartiett Publishers, Toronto, pp 251–264
Griffin JF, Smalley SR, Jewell W, Paradelo JC, Reymond RD, Hassanein RE, Evans RG (1990) Patterns of failure after curative resection of pancreatic carcinoma. Cancer 66:56–61
Harewood GC, Wiersema MJ (2002) Endosonography-guided fine needle aspiration biopsy in the evaluation of pancreatic masses. Am J Gastroenterol 97:1386–1391
Higashi T, Saga T, Nakamoto Y, Ishimori T, Mamede MH, Wada M, Doi R, Hosotani R, Imamura M, Konishi J (2002) Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med 43:173–180
Higashi T, Saga T, Nakamoto Y, Ishimori T, Fujimoto K, Doi R, Imamura M, Konishi J (2003) Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET)—usefulness and limitations in “clinical reality”. Ann Nucl Med 17:261–279
Jadvar H, Fischman AJ (2001) Evaluation of pancreatic carcinoma with FDG PET. Abdom Imaging 26:254–259
Lyshchik A, Higashi T, Nakamoto Y, Fujimoto K, Doi R, Imamura M, Saga T (2005) Dual-phase 18F-fluoro-2-deoxy-D-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging 32:389–397
Maisey NR, Webb A, Flux GD, Padhani A, Cunningham DC, Ott RJ, Norman A (2000) FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. Br J Cancer 83:287–293
Meyer W, Jurowich C, Reichel M, Steinhauser B, Wunsch PH, Gebhardt C (2003) Pathomorphological and histological prognostic factors in curatively resected ductal adenocarcinoma of the pancreas. Surg Today 30:582–587
Micke O, Bruns F, Kurowski R, Horst E, deVries AF, Hausler JW, Willich N, Schafer U (2003) Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy. Int J Radiat Oncol Biol Phys 57:90–97
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214
Mortele KJ, Lemmerling M, de Hemptinne B, De Vos M, De Bock G, Kunnen M (2000) Postoperative findings following the Whipple procedure: determination of prevalence and morphologic abdominal CT features. Eur Radiol 10:123–128
Nakata B, Chung YS, Nishimura S, Nishihara T, Sakurai Y, Sawada T, Okamura T, Kawabe J, Ochi H, Sowa M (1997) 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer 79:695–699
Pantalone D, Ragionieri I, Nesi G (2001) Improved survival in small pancreatic cancer. Dig Surg 18:41–46
Riall TS, Cameron JL, Lillemoe KD, Campbell KA, Sauter PK, Coleman J, Abrams RA, Laheru D, Hruban RH, Yeo CJ (2005) Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma—part 3: update on 5-year survival. J Gastrointest Surg 9:1191–1204
Rose DM, Delbeke D, Beauchamp RD, Chapman WC, Sandler MP, Sharp KW, Richards WO, Wright JK, Frexes ME, Pinson CW, Leach SD (1999) 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg 229:729–737
Ruf J, Lopez Hanninen E, Oettle H, Plotkin M, Pelzer U, Stroszczynski C, Felix R, Amthauer H (2005) Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI. Pancreatology 5:266–272
Scialpi M, Scaglione M, Volterrani L, Lupattelli L, Ragozzino A, Romano S, Rotondo A (2005) Imaging evaluation of post pancreatic surgery. Eur J Radiol 53:417–424
Sperti C, Pasquali C, Chierichetti F, Ferronato A, Decet G, Pedrazzoli S (2003) 8-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J Gastrointest Surg 7:953–959
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, Meisetschlager G, Busch R, Siewert JR, Schwaiger M, Fink U (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19:3058–3065
Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P (1999) Measurement of clinical and subclinical tumor response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer PET Study Group. Eur J Cancer 35:1773–1778
Zimny M, Fass J, Bares R, Cremerius U, Sabri O, Buechin P, Schumpelick V, Buell U (2000) Fluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinoma. Scand J Gastroenterol 35:883–888
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Ruf, J., Amthauer, H. (2008). Detection of Disease Recurrence and Monitoring of Therapy. In: Pancreatic Cancer. Recent Results in Cancer Research, vol 177. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-71279-4_12
Download citation
DOI: https://doi.org/10.1007/978-3-540-71279-4_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-71266-4
Online ISBN: 978-3-540-71279-4
eBook Packages: MedicineMedicine (R0)